# Chloramphenicol



EMLc | ATC codes: J01BA01

| | |
|---|---|
| **Indication** | Bacterial meningitis ICD11 code: 1D01.0Z |
| **INN** | Chloramphenicol |
| **Medicine type** | Chemical agent |
| **Antibiotic groups** | A ACCESS |
| **List type** | Core |
| **Additional notes** | Oily suspension for injection formulation is only for the presumptive treatment of epidemic meningitis in children older than 2 years and in adults. |
| **Formulations** | **Parenteral > General injections > IV:** 1 g in vial powder for injection (sodium succinate)<br>**Parenteral > General injections > IM:** 500 mg in 2 mL ampoule oily suspension for injection |
| **EML status history** | First added in 2017 (TRS 1006)<br>Changed in 2023 (TRS 1049) |
| **Sex** | All |
| **Age** | Also recommended for children |
| **Therapeutic alternatives** | The recommendation is for this specific medicine |
| **Patent information** | Patents have expired in most jurisdictions<br>Read more about patents. |
| **Wikipedia** | Chloramphenicol |
| **DrugBank** | Chloramphenicol |

## Expert Committee recommendation

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc. - the addition of new formulations of amoxicillin (dispersible, scored tablet, 250 mg and 500 mg) to the EMLc. - the deletion of oral formulations of chloramphenicol (capsule 250 mg and oral liquid 150 mg/5 mL (as palmitate)) from the EML and EMLc.

## EML recommendations: Bacterial meningitis

**First choice**

**Second choice**

cefotaxime

ceftriaxone

cefotaxime

ceftriaxone

ampicillin

benzylpenicillin

amoxicillin

chloramphenicol

amoxicillin

ampicillin

benzylpenicillin

chloramphenicol

